Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non-Small Cell Lung Cancer

被引:222
作者
Chen, Helen H. W. [2 ]
Chiu, Nan-Tsing [1 ]
Su, Wu-Chou [3 ]
Guo, How-Ran [4 ]
Lee, Bi-Fang [1 ]
机构
[1] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Nucl Med, Tainan 704, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Radiat Oncol, Tainan 704, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 704, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Environm & Occupat Hlth, Tainan 704, Taiwan
关键词
POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; METABOLIC TUMOR VOLUME; F-18-FDG PET; FLUORODEOXYGLUCOSE UPTAKE; RADIATION-THERAPY; STAGE-I; PREDICTS; SURVIVAL; RECURRENCE;
D O I
10.1148/radiol.12111148
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine whether whole-body total lesion glycolysis (TLG), which combines volumetric and metabolic information from fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), can provide a better evaluation of the prognosis for non-small cell lung cancer (NSCLC). Materials and Methods: The institutional review board approved this retrospective study, and the requirement to obtain informed consent was waived. The authors identified 105 consecutive patients with NSCLC who underwent staging FDG PET/CT before any therapy. These patients were free of brain metastasis and underwent standard treatment and subsequent clinical follow-up. Metabolic tumor volume (MTV), mean standardized uptake value (SUV), and maximum SUV of each tumor over the whole body were determined. Whole-body MTV and whole-body TLG are the summation of all the MTVs and summation of individual tumor volume multiplied by its mean SUV, respectively. Univariate and multivariate analyses were performed to assess the prognostic significance of whole-body TLG and other factors, including whole-body MTV, lung TLG, lung MTV, maximum SUV, sex, age, performance status, histologic subtype, T stage, N stage, clinical stage, and treatment method. Results: The median follow-up time was 3.1 years. The estimated median progression-free survival (PFS) and overall survival (OS) for the cohort was 10.8 months and 2.8 years, respectively. The 1-year PFS was 0.0% for patients with high whole-body TLG (>655) and 50.0% for those with low whole-body TLG (<= 655). The 1-year OS was 58.8% for patients with high whole-body TLG and 84.1% for those with low whole-body TLG. Univariate analysis showed that whole-body TLG, whole-body MTV, lung TLG, lung MTV, maximum SUV, performance status, T stage, N stage, clinical stage, and treatment type (surgery vs other) were significant prognostic factors for PFS (P < .01 for all). With use of the forward stepwise multivariate Cox proportional hazards model, whole-body TLG (hazard ratio = 2.92; 95% confidence interval: 1.62, 5.26; P < .01) and surgical treatment (hazard ratio = 4.24; 95% confidence interval: 2.54, 7.07; P < .01) remained significant in PFS. Conclusion: Whole-body TLG is of prognostic value for NSCLC. It may be a promising tool for stratifying patients with NSCLC for risk-adapted therapies. (C) RSNA, 2012
引用
收藏
页码:559 / 566
页数:8
相关论文
共 45 条
[1]   Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas [J].
Benz, Matthias R. ;
Allen-Auerbach, Martin S. ;
Eilber, Fritz C. ;
Chen, Hui J. J. ;
Dry, Sarah ;
Phelps, Michael E. ;
Czernin, Johannes ;
Weber, Wolfgang A. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (10) :1579-1584
[2]  
Biehl KJ, 2006, J NUCL MED, V47, P1808
[3]   Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma [J].
Bradley, JD ;
Ieumwananonthachai, N ;
Purdy, JA ;
Wasserman, TH ;
Lockett, MA ;
Graham, MV ;
Perez, CA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (01) :49-57
[4]   Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[5]   The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival [J].
Cerfolio, RJ ;
Bryant, AS ;
Ohja, B ;
Bartolucci, AA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (01) :151-159
[6]   18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma [J].
Costelloe, Colleen M. ;
Macapinlac, Horner A. ;
Madewell, John E. ;
Fitzgerald, Nancy E. ;
Mawlawi, Osama R. ;
Rohren, Eric M. ;
Raymond, A. Kevin ;
Lewis, Valerae O. ;
Anderson, Peter M. ;
Bassett, Roland L., Jr. ;
Harrell, Robyn K. ;
Marom, Edith M. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (03) :340-347
[7]   Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection [J].
Downey, RJ ;
Akhurst, T ;
Gonen, M ;
Vincent, A ;
Bains, MS ;
Larson, S ;
Rusch, V .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3255-3260
[8]   LUNG-TUMOR GROWTH CORRELATES WITH GLUCOSE-METABOLISM MEASURED BY FLUORIDE-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY [J].
DUHAYLONGSOD, FG ;
LOWE, VJ ;
PATZ, EF ;
VAUGHN, AL ;
COLEMAN, E ;
WOLFE, WG .
ANNALS OF THORACIC SURGERY, 1995, 60 (05) :1348-1352
[9]   Use of PET to monitor the response of lung cancer to radiation treatment [J].
Erdi, YE ;
Macapinlac, H ;
Rosenzweig, KE ;
Humm, JL ;
Larson, SM ;
Erdi, AK ;
Yorke, ED .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (07) :861-866
[10]   Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres [J].
Flamen, Patrick ;
Vanderlinden, Bruno ;
Delatte, Philippe ;
Ghanem, Ghanem ;
Ameye, Lieveke ;
Van Den Eynde, Marc ;
Hendlisz, Alain .
PHYSICS IN MEDICINE AND BIOLOGY, 2008, 53 (22) :6591-6603